A Phase 2 interventional study of Pembrolizumab in Hodgkin Lymphoma, sponsored by University of Cologne. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-06.
Sponsored by University of Cologne · Phase 2, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing pembrolizumab in Hodgkin Disease — 12 open to participants now, 20 under way, 2 of them phase 3. pembrolizumab · Hodgkin Disease.
Among the 30 studies testing pembrolizumab in Hodgkin Disease, this one is the 14th largest by planned enrollment, is one of 2 that started in 2025, is one of 22 in phase 2, reaches primary completion later than 10 of the 19 other live ones, and was the 22nd registered.
1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.
Browse Hodgkin Disease studies →12 of the 30 studies testing pembrolizumab in Hodgkin Disease are open now, in 7 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Michael Spinner, MD · Sites in United States
Ages 18+
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 18+
University of Cologne · Sites in Germany
Ages 18–65
St. Petersburg State Pavlov Medical University · Sites in Kazakhstan, Russia
Ages 18–70
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 26 · Phase 3 4
First in 2013; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 34 across the 30 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 30 have an industry lead sponsor. The 10 most frequent:
University of Cologne is the lead sponsor of 203 studies on the registry; 26 are open to participants now.
30 studies in Hodgkin Disease by University of Cologne: 5 open now, 7 under way, 1 of them phase 3. Of 22 finished, 1 (5%) have results posted.
Among the 30 studies in Hodgkin Disease by University of Cologne, this one is the 17th largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 in phase 2, and was the 28th registered.
University of Cologne’s Hodgkin Disease studies by the year they started, since 1998.
8 of the studies testing pembrolizumab in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05355051M.D. Anderson Cancer CenterA Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma | 2026-12-31 |
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT06045195University of ColognePembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma | 2027-01 |
| NCT03407144Merck Sharp & Dohme LLCSafety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | 2027-02-12 |
| NCT03618550Memorial Sloan Kettering Cancer CenterPhase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | 2027-08 |
Add all 8 to your calendar (.ics) → With an account.
Among the 30 studies testing pembrolizumab in Hodgkin Disease, from their registry updates:
Among University of Cologne’s 30 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care
Main Inclusion Criteria:
Main Exclusion Criteria:
Pembrolizumab + BrECADD
Drug: Pembrolizumab
As induction therapy, all participants will receive one dose of single-agent pembrolizumab (P) followed by two cycles of chemo-immunotherapy consisting of pembrolizumab and BrECADD (P-BrECADD). Response to induction therapy will be measured after 1x P (PET-1) and after 1x P + 2x P-BrECADD (PET-3). Further systemic treatment is PET-3-guided. Complete metabolic responses will be consolidated with two further cycles of P-BrECADD while participants with a positive PET-3 will receive four further cycles of P-BrECADD. PET-positive lesions after completion of chemo-immunotherapy will be recommended for consolidating radiotherapy according to standard of care.
progression free survival
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Jan 2027, 17 months later.
Of 180 non-industry phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's planned 17 months is below that.
Counting every sponsor, half of 203 studies reached it within 75 months; a quarter within 42 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pembrolizumab